Beta-Blocker and Heart Failure in OPTIMIZE-HF, follow-up data were limited to only 60 to 90 days after hospital discharge and collected from only a subset of participating hospitals. Outcomes may have been different over the longer follow-up. Therefore, it should be confirmed in another setting whether a long-term survival benefit could be associated with this therapeutic approach in an unselected population of patients hospitalized for HF.
The Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) studied prospectively the characteristics, treatments, and outcomes in a broad sample of patients hospitalized with HF at teaching hospitals in Japan between January 2004 and June 2005 and the outcomes including death and hospital re-admission were followed through 2007. 12, [13] [14] [15] The JCARE-CARD program enrolled 2,675 patients admitted with HF in a web-based registry at 164 participating hospitals with an average follow-up of 2.2 years. The present study was aimed to analyze the JCARE-CARD database to evaluate the relationship between discharge use of β-blockers and long-term clinical outcomes using by the regression adjustment for the propensity score, which is a statistical method that reduces confounding and bias from measured variables in observational data.
Methods

Patients
The details of the JCARE-CARD program have been described previously. 12 Briefly, eligible patients were those hospitalized with worsening HF as the primary cause of admission. JCARE-CARD enrolled a total of 2,675 patients The status of all patients was surveyed after discharge and the following information was obtained: (1) survival, (2) cause of death, and (3) the hospital re-admission due to an exacerbation of HF that required more than continuation of their usual therapy on prior admission.
Statistical Analysis
Patient characteristics and treatments were compared using Pearson χ2 test for categorical variables and unpaired t-test for continuous variables. Only patients who survived the index hospitalization were included in the follow-up analysis.
To evaluate the effects of β-blocker use on the outcomes in the present study, all effects by drugs other than the β-blocker and any possible confounding factors that may influence outcomes should be sufficiently eliminated. Propensity score adjustment has been one of the most widely employed covariate adjustment methods. 16 In the propensity score adjustment used in the observational studies, the information of covariates and confounding factors are utilized to adjust the bias. Therefore, although this study is not a prospective randomized control trial, it could enable us to evaluate the prognostic effects of β-blocker more accurately with adjustment using a propensity score method. The propensity score was created to express the likelihood for β-blocker use given the baseline characteristics and other predischarge medications as shown in Tables 1 and 2. 16 A Cox proportional hazard model was used to assess the adjusted relationship between β-blocker use at discharge and long-term outcomes. In addition to β-blocker use, age, body mass index (BMI), etiology, renal failure, hyperuricemia, anemia, chronic obstructive pulmonary disease (COPD), heart rate, plasma BNP at discharge, and propensity score were included as covariates in the model. A P-value of 0.05 was used for criteria for variables to stay in the model. SPSS version 14.0 (SAS Institute, Cary, NC, USA) was used for all statistical analyses.
Results
Patient Characteristics
Patient characteristics for the entire cohort and patients with and without receiving a prescription for a β-blocker are shown in Table 1 . The mean age was 66.3±13.7 years and 72% of the patients were male. HF etiology was ischemic in 40%, cardiomyopathic in 36%, and hypertensive in 22% of the patients. The mean LVEF was 27.1±7.3%. Among 947 patients with LVSD, 624 (66%) were treated with β-blocker at the time of hospital discharge. The majority of patients taking a β-blocker had carvedilol (89.8%) and some had other β-blockers including metoprolol (5.6%), bisoprolol (3.5%), and others (1.1%).
Patients in the group prescribed β-blocker were younger, had greater BMI, and were more likely to have cardiomyopathy as an etiology than patients who were not prescribed any β-blocker at discharge. Renal failure, hyperuricemia, anemia, and COPD were more frequent in patients not discharged on β-blocker. Vital signs including heart rate and blood pressure at discharge, echocardiographic LV diameters and LVEF did not differ between patients with and without β-blocker. Importantly, medication use other than β-blocker at hospital discharge was similar between groups ( Table 2) .
Older age, non-cardiomyopathic etiology, hyperuricemia, COPD, lower heart rate were identified as independent predictors of no β-blocker use by the logistic regression analysis ( Table 3) . Plasma BNP concentrations were not associated with the use of β-blocker.
Postdischarge Outcomes by β-Blocker Use
The long-term follow-up data could be obtained from 847 (558 and 289 for β-blocker use and no β-blocker use, respec- Table 1 . *BNP <100 pg/ml was used as a reference when the ORs were calculated.
Beta-Blocker and Heart Failure tively; P=0.999) out of 947 patients (89.4%). Mean postdischarge follow-up period was 801±300 days (2.2±0.8 years); 823±282 days for β-blocker use and 757±328 days for no β-blocker use. In the overall cohort of patients with HF and LVSD, mortality during 2.2 years after hospital discharge was 17.8%. Re-admission due to the worsening of HF was 33.5%. In the group of patients discharged on β-blocker, 14.5% of patients experienced death from any cause. In contrast, a significantly greater percentage (24.2%) of patients not prescribed a β-blocker experienced death within the same follow-up period (P=0.001; Table 4 ). The rate of cardiac death was also lower in patients on β-blocker vs those not prescribed a β-blocker (9.7% vs 15.9%) (P=0.004). There was a trend for fewer rehospitalizations in the patient group discharged on β-blocker compared with no β-blocker; however, it did not reach statistical significance (31.9% vs 36.3%, P=0.147; Table 4 ). The rates of all-cause mortality, cardiac mortality, and mortality or rehospitalization were lower in patients on β-blocker vs those not prescribed a β-blocker also at 90 days after discharge (inset figures of Figure) . We also analyzed the relationship between the daily doses of carvedilol and the long-term outcomes in patients with HF. The risk of cardiac death was significantly lower in the subgroup of patients who received ≥10 mg/day of carvedilol than in other groups who had lower doses ( Table 5) . The other outcomes including all-cause death or hospitalization did not differ between doses.
Multivariable Analysis
The effects of β-blocker use on the outcomes were tested in risk-adjusted models. The difference in mortality between the 2 groups separated early and was highly statistically significant (Figure) . After adjustment for multiple variables predictive of postdischarge mortality for β-blocker use, discharge use of β-blocker, when compared to no β-blocker use, was still associated with a reduced risk of all-cause mortality (hazard ratio (HR) 0.606, 95% confidence interval (CI) 0.377-0.974, P=0.038) ( Table 4 and Figure) . For cardiac mortality, β-blocker use was also associated with decreased risk (HR 0.517, 95%CI 0.288-0.927, P=0.027) ( Table 4 and Figure) . These relationships were remained after adjustment for covariates and propensity score (all-cause mortality; HR 0.564, 95%CI 0.358-0.889, P=0.014, cardiac mortality; HR 0.489, 95%CI 0.279-0.859, P=0.013) ( Table 4) . However, risk of hospitalization due to worsening HF and all-cause mortality or hospitalization were not associated with β-blocker use (hospitalization: HR 0.898, 95%CI 0.623-1.295 P=0.565, and all-cause death or hospitalization: HR 0.810, 95%CI 0.581-1.129, P=0.214) ( Table 4 and Figure) .
In consistent with the primary analysis, β-blocker use was associated with better outcomes in the subgroup of patients with cardiomyopathy as a cause of HF, whereas it did not affect the outcomes in the subgroup of ischemic etiology (Tables 6 and 7).
Discussion
Among patients hospitalized with HF and LVSD, β-blocker use at discharge was associated with a significantly better long-term survival. The present study extended the results of randomized clinical trials with β-blockers conducted in selected patients with systolic HF to a diverse cohort of patients hospitalized with HF. It also extended the results of OPTIMIZE-HF, in which carvedilol use at discharge was associated with reduced mortality within 30-60 days, with significant survival benefit during the long-term follow-up of 2.2 years. 10 Previous large-scale, randomized clinical trials have demonstrated significant reductions in mortality with the use of β-blockers in patients with systolic HF. 1-3 Moreover, the IMPACT-HF trial found that patients, who began carvedilol treatment before discharge, had significantly higher rates of continued β-blocker use after discharge than those who did not start β-blocker therapy. 9 Based on these results, current Table 1 .
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HF management guidelines in the USA and Europe have recommended the routine use of β-blockers for systolic HF. 4,17 Despite this situation, β-blockers remain significantly underused in these patients. 6 Beta-blocker use is particularly low in patients hospitalized for HF. In the EFFECT study, only 405 (37.7%) of 1,073 eligible patients were reported to be discharged on β-blockers. 18 Older age, non-cardiomyopathic etiology, hyperuricemia, COPD and lower heart rate were independent predictors for no β-blocker use at discharge in this study ( Table 3) . These findings are consistent with previous studies that older age and COPD are well-known predictors of low β-blocker prescription. 19-21 However, OPTIMIZE-HF registry demonstrated that β-blocker use was independently associated with lower risks of death and rehospitalization in elderly patients with HF and LVSD. 22 In addition, selective β-blockade has been recommended not to be withheld in patients with HF and moderate-to-severe COPD. 23, 24 Further studies are needed to confirm the beneficial effects of β-blocker in patients with HF associated with COPD. Figure. Kaplan -Meier survival curves free from all-cause mortality (A), cardiac mortality (B), hospitalization due to the worsening HF (C), and all-cause mortality or hospitalization (D) in hospitalized patients with β-blocker use (red line, n=558) vs non β-blocker use (black line, n=289) at discharge. Inset figures also described Kaplan-Meier survival curves free from all-cause mortality (A), cardiac mortality (B), hospitalization due to the worsening HF (C), and all-cause mortality or hospitalization (D) in hospitalized patients with β-blocker use (red line, n=558) vs non β-blocker use (black line, n=289) at 90 days after discharge. HF, heart failure; HR, hazard ratio; CI, confidence interval. Tables 1,4 .
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The present study has provided the first demonstration that there is a substantial reduction of long-term mortality associated with discharge use of β-blockers, mainly (90%) carvedilol. The survival curves diverged within the early follow-up period and the mortality differences remained statistically significant during the average follow-up of 2.2 years (Figure) . These short-term outcomes are consistent with those from IMPACT-HF and OPTIMIZE-HF. 9,10 However, these previous studies limited its follow-up to the first 60 to 90 days postdischarge and only a subset of hospitals participated in the collection of follow-up data. Therefore, JCARE-CARD was the first that clearly demonstrated the survival benefit of β-blocker use at discharge in systolic HF patients encountered in routine clinical practice. Both OPTIMIZE-HF and JCARE-CARD suggest that failure to initiate β-blocker before hospital discharge exposes patients to a substantial increased risk for HF events that could be prevented. The latest HF management guidelines now recommend whenever possible that β-blocker should be initiated before hospital discharge. 4, 17 These findings should reassure physicians that this treatment strategy is safe and effective, and provides an opportunity to significantly improve outcomes of patients with HF.
Although evidence from randomized clinical trials shows a significant survival benefit for β-blocker in systolic HF, such trials are recognized as unrepresentative of the general HF population encountered in routine clinical practice. Therefore, uncertainty pertaining to the applicability of these findings to the population of HF patients at large persists. Therefore, it is of critical importance to analyze the data of HF patients in routine clinical practice. The results from a large, representative HF population in JCARE-CARD confirmed the findings from large-scale clinical trials in that β-blocker treatment at the time of hospital discharge was associated with long-term survival benefit (Figure and Table 3) .
Beta-blocker use was associated with better outcomes in the subgroup of patients with cardiomyopathy, whereas it was not in patients with ischemic etiology (Tables 6 and 7) . Patients with ischemic heart disease were older and had higher prevalence of cormorbidities, which may in part explain the differences between these two etiologies.
Several limitations should be acknowledged in the present study. First, documentation of β-blocker prescription at hospital discharge does not reflect the level of its use after discharge or adherence to β-blocker use over time. Second, JCARE-CARD is not a prospective randomized trial and, despite covariate adjustment, other measured and unmeasured factors may have influenced outcomes. We thus cannot completely exclude other unmeasured factors that may also affect outcomes. Third, this study was not adequately powered to compare outcomes between different β-blockers, because smaller numbers of patients were discharged on β-blockers other than carvedilol, which is the only β-blocker approved for HF and is covered by insurance in Japan. Fourth, we did not collect the information regarding the reasons for no β-blocker use. The present study might have included patients with possible contraindications to β-blocker such as symptomatic bradycardia and hypotension. However, the information regarding on these patients was also not available in this study. Importantly, although the present study could not identify the reasons for no β-blocker use, β-blocker use at discharge was independently associated with a long-term survival benefit. Finally, data were dependent on the accuracy of documentation by individual hospitals that participated in this study. However, it is not the objective of this registry to restrict enrollment to the narrowly defined population of HF usually included in clinical trials but rather to include a broad range of patients reflecting the current reality of clinical practice. Despite these limitations, the present study provided clinically important findings concerning the relationship between discharge use of β-blockers and outcomes from a large, representative data set of HF patients.
Conclusions
Among patients hospitalized for HF with LVSD, treatment with β-blockers was associated with significantly reduced risk of mortality compared with patients who were not prescribed any β-blocker at discharge. Widespread application of this approach could substantially improve outcomes in the large numbers of patients with HF encountered in routine clinical practice.
